工程化益生菌用于肿瘤靶向联合化学免疫治疗
Engineered probiotics for tumor-targeted combination chemoimmunotherapy.
我们的方法将酶/前药治疗和免疫治疗整合到一个单一的细菌递送系统中,通过提供合理设计的空间控制化学免疫治疗框架,克服了传统疗法的关键局限性。
英文原题:Lymphodepleting preconditioning impairs host antitumor immunity induced by adoptive T cell therapy in mouse models.
Lymphodepleting preconditioning impairs host antitumor immunity induced by adoptive T cell therapy in mouse models.
过继性T细胞疗法(ACT)对血液系统恶性肿瘤有效,但在实体瘤中持久缓解的机制仍不清楚。
过继性T细胞疗法(ACT)对血液系统恶性肿瘤有效,但其在实体瘤中持久应答的机制仍不清楚。我们发现,能够清除已建立的小鼠肿瘤的过继转移CD8+ T细胞可促进宿主CD8+ T细胞的扩增,这些宿主细胞表现出肿瘤反应性和组织驻留表型,并参与肿瘤清除。在机制上,转移细胞产生的肿瘤坏死因子(TNF)诱导树突状细胞(DC)依赖性的宿主CD8+ T细胞扩增,从而提供针对缺乏靶抗原的ACT耐药肿瘤细胞的保护。淋巴细胞清除性预处理可促进转移细胞的扩增和原发肿瘤的清除,但会损害宿主抗肿瘤免疫,并消除针对ACT耐药肿瘤的保护作用。在人类肿瘤中,TNF/DC/CD8+ T细胞特征增强与有利的ACT应答和生存改善相关。这些发现揭示了转移CD8+ T细胞与宿主CD8+ T细胞之间由TNF依赖的相互作用所介导的持久抗肿瘤免疫,而该免疫在小鼠模型中会被淋巴细胞清除性预处理所损害,提示了一种未被充分认识的ACT耐药机制。
Adoptive T cell therapy (ACT) is effective against hematologic cancers, but the mechanisms underlying durable responses in solid tumors remain unclear. We show that adoptively transferred CD8 + T cells that eradicate established murine tumors promote expansion of host CD8 + T cells exhibiting tumor-reactive and tissue-resident phenotypes that contribute to tumor elimination. Mechanistically, tumor necrosis factor (TNF) from transferred cells induces dendritic cell (DC)-dependent expansion of host CD8 + T cells, conferring protection against ACT-resistant tumor cells lacking the targeted antigen. Lymphodepleting preconditioning promotes expansion of transferred cells and primary tumor eradication but impairs host antitumor immunity and abrogates protection against ACT-resistant tumors. In human tumors, increased TNF/DC/CD8 + T cell profiles correlate with favorable ACT responses and improved survival. These findings reveal a TNF-dependent interplay between transferred and host CD8 + T cells underlying durable antitumor immunity that is impaired by lymphodepleting preconditioning in mouse models, suggesting an underappreciated mechanism of ACT resistance.
MEMBER ACCOUNT
登录成功会直接打开下一页。